These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37914476)

  • 21. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.
    Mayer LD; Tardi P; Louie AC
    Int J Nanomedicine; 2019; 14():3819-3830. PubMed ID: 31213803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of aggressive chemotherapy for myelodysplastic syndromes.
    Dohy H; Kyo T
    Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1428-34. PubMed ID: 3247817
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy of low-dose cytarabine therapy in myelodysplastic syndromes.
    el-Mangoush M; Singh NK
    J Assoc Physicians India; 1992 Jul; 40(7):452-4. PubMed ID: 1484026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC).
    Jacoby MA; Finn L; Emadi A; Saba NS; Powell BL; Seiter K; Garcia R; Faderl S; Male HJ
    Leuk Lymphoma; 2021 Oct; 62(10):2539-2542. PubMed ID: 33974493
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals.
    Wang Q; Tardi P; Sadowski N; Xie S; Heller D; Mayer L
    Nanomedicine; 2020 Nov; 30():102275. PubMed ID: 32750494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of advanced myelodysplastic syndromes: trend toward more aggressive chemotherapy?
    Aul C; Schneider W
    Haematol Blood Transfus; 1990; 33():382-6. PubMed ID: 2323646
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
    Keating MJ; Estey E; Kantarjian H; Plunkett W; O'Brien S; Koller C; Beran M; Freireich EJ
    Leukemia; 1992; 6 Suppl 2():78-80. PubMed ID: 1578950
    [No Abstract]   [Full Text] [Related]  

  • 29. Recurrent and reversible bilateral palmar blue discoloration following administration of liposomal daunorubicin-cytarabine (Vyxeos®) for acute myeloid leukemia with myelodysplasia-related changes.
    Triesel K; Chiang T; Seabury R; Miller C
    J Oncol Pharm Pract; 2021 Sep; 27(6):1539-1541. PubMed ID: 33307969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
    Lancet JE; Cortes JE; Hogge DE; Tallman MS; Kovacsovics TJ; Damon LE; Komrokji R; Solomon SR; Kolitz JE; Cooper M; Yeager AM; Louie AC; Feldman EJ
    Blood; 2014 May; 123(21):3239-46. PubMed ID: 24687088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia.
    Benitez LL; Perissinotti AJ; Rausch CR; Klaus J; Clark SM; Filtz M; Ratermann K; Treptow C; Griffin S; Olson M; Crain M; Kadia T; Pettit K; Burke PW; Bixby DL; Marini BL
    Leuk Lymphoma; 2021 Sep; 62(9):2184-2192. PubMed ID: 33830856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
    Maakaron JE; Mims AS
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Ventricular fibrillation in a patient with myelodysplastic syndrome treated with small doses of cytarabine].
    Drzewoski J; Krykowski E; Robak T; Jerzmanowski P; Kusowska J; Koźbiał H
    Kardiol Pol; 1989; 32(4):225-8. PubMed ID: 2622113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply.
    Bernal T; Martínez-Camblor P; Sánchez-García J; Sanz G
    Leukemia; 2016 Mar; 30(3):740-1. PubMed ID: 26754826
    [No Abstract]   [Full Text] [Related]  

  • 35. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment.
    Nikanjam M; Capparelli EV; Lancet JE; Louie A; Schiller G
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):171-178. PubMed ID: 29167924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.
    Lin TL; Newell LF; Stuart RK; Michaelis LC; Rubenstein E; Pentikis HS; Callahan T; Alvarez D; Liboiron BD; Mayer LD; Wang Q; Banerjee K; Louie AC
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):163-173. PubMed ID: 31098682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of low-dose cytarabine therapy in myelodysplastic syndromes.
    el Mangoush M; Singh MK; Kumar S; Korajkio M; Gamati A
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():100. PubMed ID: 2627594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose cytarabine in myelodysplastic syndromes and acute leukemia. A comment.
    Cacciola E; Di Raimondo F; Guglielmo P; Milone G; Giustolisi R
    Acta Haematol; 1986; 75(2):125-6. PubMed ID: 3090823
    [No Abstract]   [Full Text] [Related]  

  • 40. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
    Stein EM; Fathi AT; DiNardo CD; Pollyea DA; Roboz GJ; Collins R; Sekeres MA; Stone RM; Attar EC; Frattini MG; Tosolini A; Xu Q; See WL; MacBeth KJ; de Botton S; Tallman MS; Kantarjian HM
    Lancet Haematol; 2020 Apr; 7(4):e309-e319. PubMed ID: 32145771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.